{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:35:38Z","timestamp":1776699338000,"version":"3.51.2"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jval.2024.07.017","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T01:21:25Z","timestamp":1723166485000},"page":"358-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-Utility Analysis of Antipsychotic Reduction and Discontinuation in Patients With Long-Term Schizophrenia and Psychosis in English Mental Health Trusts: The RADAR Study"],"prefix":"10.1016","volume":"28","author":[{"given":"George","family":"Bray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Moncrieff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Priebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Marston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glyn","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Pinfold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael Maree","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2024.07.017_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031660","article-title":"Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses","volume":"7","author":"Kirkbride","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jval.2024.07.017_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009010","article-title":"Inequalities in physical comorbidity: a longitudinal comparative cohort study of people with severe mental illness in the UK","volume":"5","author":"Reilly","year":"2015","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.jval.2024.07.017_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/archpsyc.64.2.242","article-title":"Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom\u2019s General Practice Rsearch Database","volume":"64","author":"Osborn","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jval.2024.07.017_bib4","series-title":"Effective Interventions in Schizophrenia: The Economic Case","author":"Andrew","year":"2012"},{"key":"10.1016\/j.jval.2024.07.017_bib5","unstructured":"National Collaborating Centre for Mental Health. Psychosis and Schizophrenia in Adults: Treatment and Management. London, United Kingdom: National Institute for Health and Care Excellence."},{"issue":"3","key":"10.1016\/j.jval.2024.07.017_bib6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jval.2024.07.017_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/cbm.724","article-title":"Outcome measures used in forensic mental health research: a structured review","volume":"19","author":"Chambers","year":"2009","journal-title":"Crim Behav Ment Health"},{"issue":"2","key":"10.1016\/j.jval.2024.07.017_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr Opin Psychiatry"},{"issue":"2","key":"10.1016\/j.jval.2024.07.017_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/schbul\/sbm159","article-title":"Methodological issues in current antipsychotic drug trials","volume":"34","author":"Leucht","year":"2008","journal-title":"Schizophr Bull"},{"issue":"3","key":"10.1016\/j.jval.2024.07.017_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/archpsyc.1995.03950150021002","article-title":"Neuroleptic withdrawal in schizophrenic patients","volume":"52","author":"Baldessarini","year":"1995","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"10.1016\/j.jval.2024.07.017_bib11","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","volume":"8","author":"Ceraso","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.jval.2024.07.017_bib12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.jval.2024.07.017_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/wps.20516","article-title":"What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?","volume":"17","author":"Correll","year":"2018","journal-title":"World Psychiatry"},{"issue":"12","key":"10.1016\/j.jval.2024.07.017_bib14","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/j.1742-1241.2007.01431.x","article-title":"Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia","volume":"61","author":"Obradovic","year":"2007","journal-title":"Int J Clin Pract"},{"issue":"1","key":"10.1016\/j.jval.2024.07.017_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2191-1991-2-8","article-title":"Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses","volume":"2","author":"Garcia-Ruiz","year":"2012","journal-title":"Health Econ Rev"},{"issue":"6","key":"10.1016\/j.jval.2024.07.017_bib16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eurpsy.2007.02.003","article-title":"Economic consequences of alternative medication strategies in first episode non-affective psychosis","volume":"22","author":"Stant","year":"2007","journal-title":"Eur Psychiatry"},{"issue":"11","key":"10.1016\/j.jval.2024.07.017_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030912","article-title":"Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction)","volume":"9","author":"Moncrieff","year":"2019","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.jval.2024.07.017_bib18","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"11","key":"10.1016\/j.jval.2024.07.017_bib19","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S2215-0366(23)00258-4","article-title":"Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial","volume":"10","author":"Moncrieff","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jval.2024.07.017_bib20","series-title":"Measuring Mental Health Needs","first-page":"163","article-title":"Costing psychiatric interventions","author":"Beecham","year":"2001"},{"issue":"1","key":"10.1016\/j.jval.2024.07.017_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10198-003-0189-y","article-title":"Economic valuation of informal care. An overview of methods and applications","volume":"5","author":"van den Berg","year":"2004","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2024.07.017_bib22","author":"Curtis"},{"issue":"5","key":"10.1016\/j.jval.2024.07.017_bib23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jval.2024.07.017_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/ar3141","article-title":"Validity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis","volume":"12","author":"Zhang","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.jval.2024.07.017_bib26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.12.012","article-title":"Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach","volume":"15","author":"Hanly","year":"2012","journal-title":"Value Health"},{"issue":"1-2","key":"10.1016\/j.jval.2024.07.017_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3959(98)00204-8","article-title":"Indirect costs of back pain in the Netherlands: a comparison of the human capital method with the friction cost method","volume":"80","author":"Hutubessy","year":"1999","journal-title":"Pain"},{"issue":"12 Suppl","key":"10.1016\/j.jval.2024.07.017_bib28","first-page":"DS59","article-title":"The consequence of production loss or increased costs of production","volume":"34","author":"Koopmanschap","year":"1996","journal-title":"Med Care"},{"issue":"9","key":"10.1016\/j.jval.2024.07.017_bib29","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2165\/00019053-200119090-00003","article-title":"Different approaches to valuing the lost\u00a0productivity of patients with migraine","volume":"19","author":"Lofland","year":"2001","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2024.07.017_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1192\/bjp.bp.114.159129","article-title":"Costs of the police service and mental healthcare pathways experienced by individuals with enduring mental health needs","volume":"210","author":"Heslin","year":"2017","journal-title":"Br J Psychiatry"},{"issue":"1","key":"10.1016\/j.jval.2024.07.017_bib33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11136-011-9927-2","article-title":"Development of a self-report measure of capability wellbeing for adults: the ICECAP-A","volume":"21","author":"Al-Janabi","year":"2012","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.jval.2024.07.017_bib34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","article-title":"Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK population study","volume":"41","author":"Hern\u00e1ndez Alava","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2024.07.017_bib35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hec.3564","article-title":"Valuing health-related quality of life: an EQ-5D-5L value set for England","volume":"27","author":"Devlin","year":"2018","journal-title":"Health Econ"},{"issue":"5","key":"10.1016\/j.jval.2024.07.017_bib37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1192\/bjp.bp.110.082453","article-title":"Is the EQ-5D fit for purpose in mental health?","volume":"197","author":"Brazier","year":"2010","journal-title":"Br J Psychiatry"},{"issue":"34","key":"10.1016\/j.jval.2024.07.017_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18340","article-title":"A\u00a0systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures","volume":"18","author":"Brazier","year":"2014","journal-title":"Health Technol Assess"},{"issue":"7","key":"10.1016\/j.jval.2024.07.017_bib39","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.socscimed.2008.06.027","article-title":"Welfarism, extra-welfarism and capability: the spread of ideas in health economics","volume":"67","author":"Coast","year":"2008","journal-title":"Soc Sci Med"},{"issue":"4","key":"10.1016\/j.jval.2024.07.017_bib40","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2022.514","article-title":"Comparison of capability and health-related quality of life instruments in capturing aspects of mental well-being in people with schizophrenia and depression","volume":"8","author":"Helter","year":"2022","journal-title":"BJPsych Open"},{"issue":"3","key":"10.1016\/j.jval.2024.07.017_bib41","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hec.3014","article-title":"Scoring the Icecap-a capability instrument. Estimation of a UK general population tariff","volume":"24","author":"Flynn","year":"2015","journal-title":"Health Econ"},{"issue":"4","key":"10.1016\/j.jval.2024.07.017_bib42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40273-014-0247-6","article-title":"An educational review of the statistical issues in analysing utility data for cost-utility analysis","volume":"33","author":"Hunter","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2024.07.017_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2021.113977","article-title":"Eliciting a monetary threshold for a year of sufficient capability to inform resource allocation decisions in public health and social care","volume":"279","author":"Kinghorn","year":"2021","journal-title":"Soc Sci Med"},{"issue":"4","key":"10.1016\/j.jval.2024.07.017_bib44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W","article-title":"Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation","volume":"6","author":"Briggs","year":"1997","journal-title":"Health Econ"},{"issue":"23","key":"10.1016\/j.jval.2024.07.017_bib45","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P","article-title":"Analysis of cost data in randomized trials: an application of the non-parametric bootstrap","volume":"19","author":"Barber","year":"2000","journal-title":"Stat Med"},{"issue":"8","key":"10.1016\/j.jval.2024.07.017_bib46","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hec.635","article-title":"Representing uncertainty: the role of cost-effectiveness acceptability curves","volume":"10","author":"Fenwick","year":"2001","journal-title":"Health Econ"},{"issue":"4","key":"10.1016\/j.jval.2024.07.017_bib47","first-page":"1","article-title":"Multiple imputation by chained equations (MICE): implementation in Stata","volume":"45","author":"Royston","year":"2011","journal-title":"J\u00a0Stat Softw"},{"issue":"8","key":"10.1016\/j.jval.2024.07.017_bib48","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40273-018-0650-5","article-title":"Sensitivity analysis for not-at-random missing data in trial-based cost-effectiveness analysis: a tutorial","volume":"36","author":"Leurent","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"9831","key":"10.1016\/j.jval.2024.07.017_bib49","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2024.07.017_bib50","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1192\/bjp.157.6.853","article-title":"The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients","volume":"157","author":"Birchwood","year":"1990","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jval.2024.07.017_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1031159","article-title":"Cost-effectiveness of peer-supported self-management for people discharged from a mental health crisis team: methodological challenges and recommendations","volume":"14","author":"Le Novere","year":"2023","journal-title":"Front Psychiatry"},{"issue":"2","key":"10.1016\/j.jval.2024.07.017_bib52","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/1356389018802134","article-title":"Building programme theory to develop more adaptable and scalable complex interventions: realist formative process evaluation prior to full trial","volume":"25","author":"Brand","year":"2019","journal-title":"Evaluation"},{"issue":"1","key":"10.1016\/j.jval.2024.07.017_bib53","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1192\/bjp.2017.10","article-title":"Recovering Quality of Life (ReQoL): a new generic self-reported outcome measure for use with people experiencing mental health difficulties","volume":"212","author":"Keetharuth","year":"2018","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jval.2024.07.017_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100803","article-title":"How do participants in clinical trials compare with other patients with schizophrenia?","volume":"22","author":"Freudenthal","year":"2021","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.jval.2024.07.017_bib55","series-title":"Efficiency in Mental Health Randomised Trials","author":"Liu","year":"2021"},{"issue":"7","key":"10.1016\/j.jval.2024.07.017_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234996","article-title":"Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia","volume":"15","author":"Jin","year":"2020","journal-title":"PLoS One"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524028006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524028006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T05:10:53Z","timestamp":1740546653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524028006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1098301524028006"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.07.017","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Utility Analysis of Antipsychotic Reduction and Discontinuation in Patients With Long-Term Schizophrenia and Psychosis in English Mental Health Trusts: The RADAR Study","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}